ClinicalTrials.gg
Active, not recruitingNCT07412275MILAUpdated Nov 19, 2026

Microwave Intervention Under Local Anesthesia

An interventional study of Local Anesthesia (lidocaine hydrochloride) in Localised Prostate Cancer, sponsored by Koelis. Active, not recruiting at 2 sites in 2 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Koelis · Not applicable, Interventional, and Other

How we know

Updated Nov 19, 2026Now Active, not recruitingNow Recruiting+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 236 studies in Prostatic Neoplasms with a site in Belgium — 42 open to participants now, 77 under way, 33 of them phase 3. Prostatic Neoplasms · Belgium.

Enrollment
195th of 206
20 · median 283
Started
2026
with 8 others
No phase
31 of 236
11 open now
Primary completion
2027-06
later than 47 of 76 live
Registered
234th of 236
by date

Among the 236 studies in Prostatic Neoplasms with a site in Belgium, this one is the 195th largest by enrollment of the 206 interventional ones that give a count, is one of 9 that started in 2026, is one of 31 with no phase, reaches primary completion later than 47 of the 76 other live ones, and was the 234th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

42 of the 236 studies in Prostatic Neoplasms with a site in Belgium are open now. Recruiting first, the newest first:

37 more — sign in →

All 42 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 236 studies in Prostatic Neoplasms with a site in Belgium, or all of them as a file.
02

Study summary

This study aims to evaluate the feasibility of performing a focal Targeted Microwave Ablation (TMA) procedure using Koelis TMA® under local anesthesia in patient with localized prostate cancer.

Eligible patients will undergo the procedure under local anesthesia instead of general anesthesia or deep sedation as part of their routine clinical care.

The primary objective is to assess the feasibility of completing the procedure under local anesthesia, defined by the proportion of patients in whom the procedure is successfully completed under local anesthesia. Secondary objectives include the assessment of safety, ease of performance, patient satisfaction, and the use of analgesic medication.

This study is designed as a feasibility clinical investigation conducted in a routine clinical practice setting.

Read the detailed description

This clinical investigation is a prospective feasibility study designed to evaluate the feasibility of performing a focal Targeted Microwave Ablation (TMA) procedure using Koelis TMA® under local anesthesia in patient with localized prostate cancer. Koelis TMA® is a CE-marked medical device use without any modification to the device's intended use.

The study will be conducted in a routine clinical care setting. Eligible patients requiring the procedure will be included after providing informed consent.

The study consists of four visits. At the inclusion visit (Visit 0), patient eligibility will be confirmed and baseline data will be collected. The intervention will be performed during Visit 1 under local anesthesia according to standard clinical practice. A follow-up phone call (Visit 2) will be conducted 7 days after the procedure (±2 days) to assess safety and tolerability data. The end-of-study visit (Visit 3) will take place 1 month after the intervention (±7 days) during a routine follow-up consultation.

The primary objective of the study is to assess the feasibility of performing the procedure under local anesthesia. Feasibility will be evaluated by the proportion of patients in whom the procedure is successfully completed under local anesthesia. If the patient presents marked discomfort, pain, or any other symptoms that make the continuation of the procedure inappropriate, it may be interrupted at his request or at the initiative of the investigator. Local anesthesia can therefore be converted to general anesthesia or deep sedation to allow treatment to continue.

Secondary objectives include the assessment of procedure tolerability, safety, ease of performance as assessed by the operator, patient satisfaction related to anesthesia, and the amount of analgesic or pain medication administered during the study period.

03

Conditions studied

  • Localised Prostate Cancer

Browse trials for

Keywords

  • Localised prostate cancer
  • TMA
  • Local anesthesia
  • Koelis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age>18 years old
  • Patient undergoing Koelis TMA® intervention
  • Patient is suitable for general, local anesthesia as well as sedation
  • No psychiatric illness that would prevent or optimal treatment and follow-up
  • Free, informed and written consent, dated and signed by the patient and the investigator, no later than the day of inclusion and before any examination required by the study.
  • Patient affiliated to a social security scheme or beneficiary of such a scheme in accordance with the regulations in force.

Exclusion criteria

Exclusion Criteria:

  • Severe illness within the last 6 months before the screening visit, including any of the following: uncontrolled congestive heart failure, uncontrolled angina pectoris, myocardial infarction, stroke.
  • Ineligibility for a Koelis TMA® intervention
  • to general anesthesia and deep sedation.
  • Uncontrolled coagulopathies or bleeding disorder
  • A person already participating in an interventional clinical study.
  • A person placed under judicial protection, guardianship, or legal supervision and incapable of freely giving .
  • Patient detained in an institution by medical or judicial decision.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Local Anesthesia

    Patient undergoing the focal targeted microwave ablation procedure performed under local anesthesia using the Koelis TMA®

    Procedure: Local Anesthesia (lidocaine hydrochloride)

Interventions

  • ProcedureLocal Anesthesia (lidocaine hydrochloride)

    Participants will receive the focal treatment performed with Koelis TMA® under local anesthesia

06

What researchers measure

Primary outcomes

  1. Feasibility of focal TMA therapy under local anesthesia in patients with localized prostate cancer

    Feasibility will be assessed by the rate of complete procedure performed under local anesthesia, defined as the proportion of patients in whom the procedure is completed under local anesthesia without the unplanned use of general anesthesia or sedation or premature termination of treatment

    Time frame: Day 0 - Intervention

Secondary outcomes

  1. Immediate Patient satisfaction regarding the procedure under local anesthesia

    The patient's satisfaction regarding the TMA procedure will be assessed by a questionnaire after the procedure

    Time frame: Day 0 - Intervention

  2. 1 month patient satisfaction regarding the procedure under local anesthesia

    The patient's satisfaction regarding the TMA procedure will be assessed by a questionnaire 1 month after the procedure

    Time frame: 1 month

  3. Ease of performing the procedure from the operator's point of view

    The ease of performing the procedure will be evaluated by a score given by the operator (1: very easy; 2: easy; 3: moderate; 4: difficult, 5: very difficult).

    Time frame: Day 0 - Intervention

  4. Patient's level of pain at the time of administration of local anesthesia

    The patient's average pain level will be assessed during the administration of local anesthesia by a numerical pain rating scale from 0 to 10.

    Time frame: Day 0 - Intervention

  5. Patient's pain level during the TMA treatment,

    The patient's average pain level will be assessed during microwave ablation via a numerical pain rating scale from 0 to 10.

    Time frame: Day 0 - Intervention

  6. To assess the patient's level of pain after treatment,

    The patient's average pain level will be assessed 1 hour after treatment via a numerical pain rating scale from 0 to 10.

    Time frame: Day 0 - Intervention

  7. To evaluate the duration of the different stages of the procedure,

    Description of the duration of the different stages of the ablation procedure will be evaluated by: 1. The duration of the local anesthesia (minutes) 2. Microwave ablation treatment duration (minutes) 3. The duration of the intervention (minutes) (start-end of the procedure) 4. The time spent by the patient in the hospital post-procedure (hours)

    Time frame: Day 0 - Intervention

  8. Success of the completion of the procedure

    The success of the completion/procedure will be assessed by the percentage of recovery of the lesion to be treated by microwave ablations

    Time frame: Day 0 - Intervention

  9. Feasibility of performing a TMA procedure in ambulatory setting

    The feasibility of ambulatory treatment will be assessed based on the percentage of hospitalizations lasting less than 12 hours.

    Time frame: Day 0 - Intervention

  10. Tolerance of performing the procedure under local anesthesia,

    Safety will be assessed by the number and severity of procedure-related adverse events, collected throughout the duration of the study

    Time frame: 1 month

  11. Amount of medication received by the patient

    The amount of medication received as measured by the amount of analgesic/painkiller received by the patient throughout the duration of the study

    Time frame: 1 month

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jun 2027, 11 months after the start.

Of 58 industry-sponsored interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 72. This study's planned 11 months is below that.

Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: start Jun 2026 → Jul 2026, primary completion May 2027 → Jun 2027 and completion Jun 2027 → Jul 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2026
First posted
Feb 17, 2026
StartActual
Jul 8, 2026was Jun 2026
Primary completionEst.
Jun 8, 2027was May 2027
CompletionEst.
Jul 8, 2027was Jun 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting→Active, not recruiting
changed Nov 18, 2026 · changed Nov 19, 2026
Sites
2 sites changed recruiting status (1 now recruiting, 1 now not yet recruiting)
Show 2 sites
  • Institut Jules Bordet · Brussels, Belgiumno status→Recruiting
  • Hôpital Cochin Port Royal · Paris, Franceno status→Not yet recruiting
Nov 18, 2026
Start date
Jun 15, 2026→Jul 8, 2026 (actual)
Nov 18, 2026
Primary completion
May 15, 2027→Jun 8, 2027
Nov 18, 2026
Study completion
Jun 15, 2027→Jul 8, 2027
Nov 18, 2026
Show all 2 updates
  1. Nov 19, 2026
    Recruiting→Active, not recruiting
    + 2 other changes: contact details and site details
  2. Nov 18, 2026
    Not yet recruiting→Recruiting
    2 sites changed recruiting status (1 now recruiting, 1 now not yet recruiting)
    Show 2 sites
    • Institut Jules Bordet · Brussels, Belgiumno status→Recruiting
    • Hôpital Cochin Port Royal · Paris, Franceno status→Not yet recruiting
    Start date Jun 15, 2026→Jul 8, 2026 (now actual)
    Primary completion May 15, 2027→Jun 8, 2027
    Study completion Jun 15, 2027→Jul 8, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07412275
Lead sponsor
Koelis
Responsible party
Sponsor
First posted
Feb 17, 2026
Start date
Jul 8, 2026
Primary completion
Jun 8, 2027 (estimated)
Completion
Jul 8, 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

ANRACT Julien, MD
principal investigator · APHP - Hôpital Cochin Port Royal

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion